Potassium Acid Phosphate

Neonatal

FORM Oral solution containing phosphate 1mmol/ml / potassium 1mmol/ml

INDICATION Prevention of metabolic bone disease in Premature neonates < 32 weeks.
.

DOSE RANGE

AGE	DOSE	FREQUENCY	ROUTE
Birth to 6 months	0.5mmol/kg/dose Adjust dose according to response up to maximum of 1.5mmol/kg/dose).	TWICE daily	Oral

Commencement of treatment – following establishment of enteral feeds (at least 100ml/kg/day tolerated)

Dose should be adjusted if serum phosphate is outside the normal range of 1.8 – 2.6mmol/L

CAUTIONS, CONTRA-INDICATIONS AND SIDE EFFECTS
- See Summary of Product Characteristics and most recent edition of BNF for Children (links below)

FURTHER INFORMATION

- Also started where biochemistry shows hypophosphataemia (PO4 < 2mmol/L) or significantly raised alkaline phosphatase
  Use with caution in renal failure
- Contains 1mmol/ml potassium
- Treatment will usually stop prior to discharge
- Phosphate supplementation will usually cease prior to discharge home

STORAGE Room temperature. Store in fridge or at room temperature depending on manufacturer once opened.

LICENSED STATUS Unlicensed special product

LINKS BNF for Children: / Electronic Medicines Compendium

APPLICABLE POLICIES West of Scotland Neonatal Guidelines:

Consult local policy if applicable

Document Number:	002	Supersedes:	001
Prepared by:	WoS Neo Pharm Group	Checked by	Marie L Currie
Date prepared	Aug 2016	Date updated	January 2019
Updated by	Peter Mulholland	Review Date	January 2022

Dose may vary depending on indication, age, renal function, hepatic function, and concomitant medications. This monograph should be used in conjunction with the package insert, BNF for Children, and Summary of Product Characteristics. For further advice contact your clinical pharmacist or pharmacy department.